Allarity Therapeutics, Inc.
ALLR
$1.28
$0.032.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -26.82% | -13.29% | -71.41% | -17.24% | -21.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -4.39% | -- | -- |
| Total Operating Expenses | -35.37% | -10.64% | -55.75% | -3.52% | 22.60% |
| Operating Income | 35.37% | 11.46% | 60.12% | 3.52% | -22.60% |
| Income Before Tax | -46.77% | -0.66% | 54.74% | 76.55% | -42.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.77% | -0.66% | 54.74% | 75.79% | -42.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.77% | -0.66% | 54.74% | 75.79% | -42.42% |
| EBIT | 35.37% | 11.46% | 60.12% | 3.52% | -22.60% |
| EBITDA | 36.01% | -- | 60.22% | 3.80% | -22.28% |
| EPS Basic | -43.34% | 29.74% | 87.72% | 97.53% | 95.53% |
| Normalized Basic EPS | -43.41% | 29.77% | 87.73% | 86.75% | 95.42% |
| EPS Diluted | -43.34% | 29.74% | 87.72% | 97.53% | 95.53% |
| Normalized Diluted EPS | -43.41% | 29.77% | 87.73% | 86.75% | 95.42% |
| Average Basic Shares Outstanding | 2.36% | 43.26% | 268.61% | 835.39% | 3,013.02% |
| Average Diluted Shares Outstanding | 2.36% | 43.26% | 268.61% | 835.39% | 3,013.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |